Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Nurix Therapeutics (NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation (ODD) from the FDA for treating Waldenström macroglobulinemia (WM). Bexobrutideg is an oral, brain-penetrant BTK degrader currently in Phase 1a/b clinical trials for relapsed/refractory B-cell malignancies.
The ODD grants several benefits including tax credits for clinical testing, FDA fee waivers, and seven years of market exclusivity upon approval. The drug represents a new class of targeted protein degraders, marked by the novel 'deg' suffix, distinguishing it from traditional inhibitors that use the 'ib' suffix.
The designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia. The drug's mechanism involves catalytic degradation of target proteins through the proteasome, potentially eliminating mutant oncoproteins resistant to inhibitor therapy.
Nurix Therapeutics (NRIX) has granted inducement awards to 13 new employees on March 11, 2025, as approved by the company's Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The awards include:
- Stock options to purchase 157,150 shares with a 10-year term and $13.90 exercise price
- Restricted stock unit awards (RSUs) representing 107,500 shares
The stock options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. RSUs also vest over 4 years, with 25% vesting on April 30, 2026, and the remainder vesting quarterly. Both awards require continued employment with Nurix for vesting.
Nurix Therapeutics (Nasdaq: NRIX) has appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D. to its board of directors. Dr. Baynes, currently executive vice president and chief medical officer of Eikon Therapeutics, brings over 22 years of clinical leadership experience in pharmaceutical and biotech companies.
Previously serving as chief medical officer at Merck, Dr. Baynes supervised the clinical portfolio and developed strategies for numerous medicines, including pembrolizumab (Keytruda). He has been a member of Nurix's Medical Advisory Board since 2023 and has expressed particular interest in the company's protein degradation science and clinical trials of NX-5948 in patients with CLL and Waldenström macroglobulinemia.
Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines for cancer and inflammatory diseases, has announced its participation in two major investor conferences in March 2025.
The company's leadership, including President and CEO Arthur T. Sands, M.D., Ph.D., and CFO Hans van Houte, will attend the Jefferies Biotech on the Beach Summit in Miami Beach for one-on-one meetings on March 11, 2025. They will also participate in the Barclays 27th Annual Global Healthcare Conference in Miami Beach, featuring a fireside chat on March 12, 2025, from 10:00-10:25 a.m. ET.
The fireside chat will be accessible through a live webcast on the Investors section of Nurix's website, with the recording available for 30 days following the event.
Nurix Therapeutics (NRIX) has granted inducement awards to nine new employees as of February 11, 2025. The awards, approved under Nasdaq Listing Rule 5635(c)(4), include stock options to purchase 208,350 shares and restricted stock unit awards (RSUs) for 272,850 shares of common stock.
The stock options, priced at $17.12 per share, will vest over four years with 25% vesting after one year and the remainder vesting monthly. They have a ten-year term. The RSUs will also vest over four years, with 25% vesting after one year and the remainder vesting quarterly. Vesting start dates are January 30, 2025, for employees hired before January 31, 2025, and April 30, 2025, for those hired after.
Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's president and CEO, Arthur T. Sands, M.D., Ph.D., will engage in a fireside chat on Tuesday, February 11, 2025, at 12:40 p.m. ET.
The company, which focuses on developing innovative treatments for cancer and inflammatory diseases, will make the event available through a live webcast. Interested parties can access the webcast through the Investors section of Nurix's website, and the recording will remain accessible for 30 days following the event.
Nurix Therapeutics (NRIX) reported significant progress in its fourth quarter and fiscal year 2024. The company achieved a 75.5% objective response rate in its Phase 1 study of NX-5948 for CLL/SLL patients. NX-5948 received both PRIME designation from European Medicines Agency and Fast Track designation from FDA.
Financial highlights include cash and marketable securities of $609.6 million. Revenue for FY2024 was $54.5 million, down from $77.0 million in FY2023. Net loss increased to $193.6 million ($2.88 per share) compared to $143.9 million ($2.65 per share) in FY2023.
The company appointed John Northcott as Chief Commercial Officer and plans to launch pivotal clinical trials for NX-5948 in 2025. Research and development expenses increased to $221.6 million in FY2024 from $189.1 million in FY2023.
Nurix Therapeutics (NRIX) has appointed John Northcott as Chief Commercial Officer. Northcott brings over 20 years of biopharmaceutical experience, notably in commercializing the BTK inhibitor ibrutinib. The appointment comes as Nurix prepares to launch its pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and other potential B-cell malignancies.
Northcott's recent roles include serving as CCO at Arvinas (2022-2024), where he built commercial infrastructure for a novel breast cancer treatment, CCO at Nektar Therapeutics (2019-2022), and CCO at Pharmacyclics (2015-2019), where he led the successful commercialization of ibrutinib. His experience spans both pre-launch planning and on-market commercialization in hematology, oncology, and other therapeutic areas.
Nurix Therapeutics (NRIX) has outlined its key objectives for 2025, highlighting significant progress in clinical trials and business development. The company reported impressive clinical responses from its NX-5948 Phase 1a/1b trial, achieving a 75.5% objective response rate in chronic lymphocytic leukemia patients. NX-5948 received Fast Track Designation from the FDA and PRIME designation from the European Medicines Agency.
The company plans to initiate pivotal studies for NX-5948 in 2025 and expand its development in additional cancer indications and inflammatory diseases. Nurix maintains a strong financial position with an estimated $609.6 million in cash and investments at fiscal 2024 year-end, expected to fund operations into the first half of 2027.
Key developments include the advancement of partnered programs in inflammation and immunology, including degraders of IRAK4 and STAT6, and investment in their DEL-AI discovery engine for novel degrader-based treatments.
Nurix Therapeutics (NRIX), a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's president and CEO, Arthur T. Sands, M.D., Ph.D., will deliver a corporate update presentation on Monday, January 13, 2025, at 3:00 p.m. PT in San Francisco.
The presentation will be accessible through a live webcast, with a link available in the Investors section of the Nurix website. For those unable to attend live, the webcast recording will remain accessible for 30 days following the event.